Blog
RSS FeedPosted by Michael Wonder on 12 Apr 2021
Prevalence of immature survival data for anti-cancer drugs presented to the National Institute for Health and Care Excellence and impact on decision-making
12 April 2021 - This research aims to explore how often NICE uses immature overall survival data to inform reimbursement ...
Posted by Michael Wonder on 01 Feb 2021
Determinants of managed entry agreements in the context of health technology assessment: a comparative analysis of oncology therapies in four countries
29 January 2021 - Managed entry agreements are increasingly used to address uncertainties arising in the health technology assessment process due ...
Posted by Michael Wonder on 22 Dec 2020
Shared decision making is an integral part of healthcare, says NICE
22 December 2020 - Shared decision making between patients and clinicians should be embedded throughout healthcare services, says NICE, in draft ...
Posted by Michael Wonder on 12 Nov 2020
Expertise, experience, and excellence. Twenty years of patient involvement in health technology assessment at NICE: an evolving story
10 November 2020 - From its inception in 1999, NICE committed to including the expertise, experiences, and perspectives of lay people, ...
Posted by Michael Wonder on 16 Oct 2020
NICE gears up to support world evidence-based health care day
16 October 2020 - Inaugural World Evidence-based Health care Day takes place on Tuesday 20 October 2020. ...
Posted by Michael Wonder on 05 Sep 2020
Real world evidence to support payer/HTA decisions about highly innovative technologies in the EU—actions for stakeholders
3 September 2020 - There are divergent views on the potential of real world data to inform decisions made by regulators, ...
Posted by Michael Wonder on 12 Jul 2020
Does cost effectiveness analysis really need to abandon the incremental cost effectiveness ratio to embrace net benefit?
10 July 2020 - The central task of cost-effectiveness analysis is to identify strategies that maximise health within finite budgets. ...
Posted by Michael Wonder on 12 Jul 2020
Why it’s time to abandon the ICER
10 July 2020 - The incremental cost-effectiveness ratio (ICER) is the most commonly reported summary measure for economic evaluations of health ...
Posted by Michael Wonder on 11 May 2020
Exploration of the visibility of patient input in final recommendation documentation for three health technology assessment bodies
7 May 2020 - Health technology assessment recommendations informed by patient concerns are seen to ensure democracy and legitimacy. ...
Posted by Michael Wonder on 12 Mar 2020
Defining the role of the public in Health Technology Assessment (HTA) and HTA-informed decision-making processes
10 March 2020 - The terminology used to describe community participation in health technology assessment is contested and frequently confusing. ...
Posted by Michael Wonder on 04 Feb 2020
Broader types of data to be used in development of NICE guidance
4 February 2020 - An expanded evidence base could allow NICE to address evidence gaps and enhance reviews of the impact ...
Posted by Michael Wonder on 17 Jan 2020
Use of patient preference studies in HTA decision making: a NICE perspective
16 January 2020 - Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee ...
Posted by Michael Wonder on 03 Dec 2019
The use of risk-sharing contracts in health care: theoretical and empirical assessments
3 December 2019 - The aim of this review is to provide a summary of the literature on risk-sharing agreements, including ...
Posted by Michael Wonder on 02 Oct 2019
Advancing patient engagement
2 October 2019 - It’s widely accepted that seeking patient input into their health and care improves outcomes for them and ...
Posted by Michael Wonder on 27 Aug 2019
Incorporating affordability concerns within cost-effectiveness analysis for health technology assessment
27 August 2019 - New framework considers the scale, time profile, and uncertainty of budget impacts. ...